Ulotaront (SEP-363856), a novel investigational drug, by Sumitomo Pharma/Otsuka Pharmaceuticals, has shown promise as a potential alternative treatment method for schizophrenia, as it lessens the negative metabolic side effects
TAAR1 has emerged as a promising target in the treatment of schizophrenia and other psychiatric disorders, as it modulates dopaminergic, serotonergic, and glutamatergic signaling, thereby regulating aspects of reward processing.
Ulotaront is being jointly developed and commercialized as part of a collaboration between Sumitomo Pharma, its US subsidiary Sumitomo Pharma America (SMPA), and Otsuka. The company presented a poster for its dr...
